Last reviewed · How we verify
NCT04539717
FAST (Focused Abbreviated Screening Technique)-MRI Study
trial in Hepatocellular Carcinoma (HCC) in 820 participants. Enrolling by invitation.
31 May 2026
Quick facts
| Lead sponsor | Icahn School of Medicine at Mount Sinai |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 820 |
| Start date | 17 August 2020 |
| Primary completion | 31 May 2026 |
| Estimated completion | 31 May 2026 |
| Sites | 2 locations across United States |
Conditions studied
- Hepatocellular Carcinoma (HCC) — all drugs for Hepatocellular Carcinoma (HCC) →
- Liver Cirrhosis — all drugs for Liver Cirrhosis →
Sponsor
Icahn School of Medicine at Mount Sinai
Who can join
18 and older, any sex, with Hepatocellular Carcinoma (HCC) or Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to compare the diagnostic value of a reconstructed abbreviated Magnetic Resonance Imaging (MRI) from a full clinical exam, compared to ultrasound (US) for screening of liver cancer. Blood markers will be evaluated to determine their correlation to imaging. This study will help to determine whether abbreviated MRI is superior to ultrasound for diagnosis of liver cancer.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Risk stratification and early detection biomarkers for precision HCC screening.
Lee YT, Fujiwara N, Yang JD, Hoshida Y. · · 2023 · cited 90× · PMID 36082510 · DOI 10.1002/hep.32779 -
Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma.
Lehrich BM, Zhang J, Monga SP, Dhanasekaran R. · · 2024 · cited 76× · PMID 38104635 · DOI 10.1016/j.jhep.2023.11.030 -
Persisting challenges in the early detection of hepatocellular carcinoma.
Arvind A, Redmon K, Singal AG. · · 2025 · cited 3× · PMID 39943795 · DOI 10.1080/14737140.2025.2467184 -
Quality of Gadoxetate-enhanced MRI versus US during Hepatocellular Carcinoma Screening in Participants with Cirrhosis.
Lewis S, Wildman-Tobriner B, Cuevas J, Calle S, et al · · 2026 · cited 1× · PMID 41665498 · DOI 10.1148/radiol.251497 -
Abbreviated MRI-Based Surveillance Strategies for Early Hepatocellular Carcinoma Detection.
Park HJ, Kim DW, Choi WM, Kim SY. · · 2025 · cited 1× · PMID 40502477 · DOI 10.3348/jksr.2024.0153 -
Abbreviated gadoxetic acid-enhanced MRI versus ultrasonography for HCC surveillance in high-risk patients: A randomized trial protocol.
Park HJ, Choi J, Kim DW, Choi SH, et al · · 2025 · PMID 41481895 · DOI 10.1097/hc9.0000000000000839 -
[Recent Updates of Abbreviated MRI for Hepatocellular Carcinoma Screening].
Kim JW, Lee CH. · · 2021 · PMID 36238735 · DOI 10.3348/jksr.2021.0025
Verify or expand the search:
- PubMed search for NCT04539717
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatocellular Carcinoma (HCC)
Currently open trials in the same condition.
- NCT07070076 — A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Ther · NA · recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
- NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
- NCT07490262 — A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular · Phase 2, PHASE3 · recruiting
- NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting
Other Icahn School of Medicine at Mount Sinai trials
Trials by the same sponsor.
- NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
- NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
- NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
- NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
- NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04539717 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
- Last refreshed: 8 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04539717.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing